Please assess the completion status of the following clinical trial:

Trial Title: Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged \>= 18 years.~* Patients with severe persistent allergic asthma with the following characteristics:~* FEV1 (Forced Expiratory Volume in One Second) \<80% of predicted.~* Frequent daily symptoms (\>=4 days/week on average) or nocturnal awakening (\>=1/week on average).~* Multiple severe asthma exacerbations: either \>=2 severe asthma exacerbations having required an unscheduled medical intervention with systemic corticosteroid in the past year, or hospitalization (including emergency room treatment) for an asthma exacerbation in the past year.~* Despite a high dose inhaled corticosteroid \>1000 mg beclomethasone dipropionate or equivalent and a inhaled long-acting B2-agonist.~* With an allergy to a perennial allergen demonstrated with convincing criteria, i.e. positive prick skin test or in vitro reactivity to a perennial aeroallergen (RAST).~* Total serum IgE level \>= 30 to \<=700 IU/ml and suitable serum total IgE level and weight according to Xolair dosing tablets.~Exclusion Criteria:~* Age \< 18 years.~* Smoking history \> 20 pack years.~* Patients who have had an asthma exacerbation during the 4 weeks prior to randomization~* History of food or drug related severe anaphylactoid or anaphylactic reaction~* Elevated serum IgE levels for reasons other than allergy (e.g. parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich Syndrome or allergic bronchopulmonary aspergillosis).~* Patients with active cancer, suspicion of cancer or any history of cancer.~* Pregnant women.~* Known hypersensitivity to omalizumab or to one of its components.~* Patients already treated with omalizumab (indeed a previous treatment with omalizumab could have modified the FceRI expression).~* Patients who had participated in a clinical trial in the past 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: ACTIVE_COMPARATOR): Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).